Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cencer: Analysis of the on-trial cases for the SCALOP trial

Comparison of investigator-delineated gross tumour volumes and quality assurance in pancreatic cencer: Analysis of the on-trial cases for the SCALOP trial

BACKGROUND AND PURPOSE:<br/> To evaluate the variation in investigator-delineated volumes and assess plans from the radiotherapy trial quality assurance (RTTQA) program of SCALOP, a phase II trial in locally advanced pancreatic cancer. <br/>MATERIALS AND METHODS:<br/> Participating...

Full description

Bibliographic Details
Main Authors:	Fokas, E, Spezi, E, Patel, N, Hurt, C, Nixon, L, Chu, K, Staffurth, J, Abrams, R, Mukherjee, S
Format:	Journal article
Published:	Elsevier 2015

Similar Items

Improving radiotherapy quality assurance in clinical trials: assessment of target volume delineation of the pre-accrual benchmark case.
by: Gwynne, S, et al.
Published: (2013)

Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer
by: Hurt, C, et al.
Published: (2017)

Gemcitabine-based or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): a multicentre, randomised, phase 2 trial.
by: Mukherjee, S, et al.
Published: (2013)

CENCER IN IRAN
by: A. Habibi
Published: (1974-12-01)

A comparison of four target volume definitions for pancreatic cancer: Two concepts including the lymphatics (RTOG and German multi-centre neoadjuvant trial) and two concepts only treating the primary tumour (Michigan and UK-SCALOP)
by: Fokas, E, et al.
Published: (2012)

Standard or high dose chemoradiotherapy, with or without the protease inhibitor nelfinavir, in patients with locally advanced pancreatic cancer: the phase 1/randomised phase 2 SCALOP-2 trial
by: Mukherjee, S, et al.
Published: (2024)

The influence of dose distribution on treatment outcome in the SCOPE 1 oesophageal cancer trial
by: Carrington, E, et al.
Published: (2016)

SCALOP-2: A randomised trial of induction GEMABX followed by chemoradiation (high/standard dose radiation) +/-nelfinavir for locally advanced pancreatic cancer: results of the dose-finding component
by: Mukherjee, S, et al.
Published: (2018)

A Comparison of 4 Target Volume Definitions for Pancreatic Cancer: Two Concepts Including the Lymphatics (RTOG and ARO) and 2 Concepts Only Treating the Primary Tumor (Michigan and UK-SCALOP)
by: Brunner, T, et al.
Published: (2012)

4DCT oesophageal tumour delineation in SCOPE2 – how is radiotherapy quality assurance beneficial?
by: Cox, S, et al.
Published: (2018)

Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
by: Strauss, V, et al.
Published: (2019)

The effect of dose escalation on gastric toxicity when treating lower oesophageal tumours: A radiobiological investigation
by: Carrington, R, et al.
Published: (2015)

Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)
by: Victoria Y. Strauss, et al.
Published: (2019-02-01)

SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
by: Virdee, P, et al.
Published: (2017)

SCALOP: sequence-based antibody canonical loop structure annotation
by: Wong, W, et al.
Published: (2018)

P-233: SCALOP-2: A multi-centre randomised study of induction chemotherapy followed by capecitabine (+/- nelfinavir) with high or standard dose radiotherapy for locally advanced non-metastatic pancreatic cancer
by: Virdee, P, et al.
Published: (2017)

SCALOP-2: A multi-centre randomised trial of induction chemotherapy followed by capecitabine +/-nelfinavir with high or standard dose radiotherapy for locally advanced pancreatic cancer (LAPC): Results of stage 1 - the non-randomised dose-finding component
by: Mukherjee, S, et al.
Published: (2018)

Gross tumour delineation on computed tomography and positron emission tomography-computed tomography in oesophageal cancer: A nationwide study
by: M.E. Nowee, et al.
Published: (2019-01-01)

Quality Assurance for Clinical Trials
by: Geoffrey Stephen Ibbott, et al.
Published: (2013-12-01)

A phase-I trial of pre-operative, margin intensive, stereotactic body radiation therapy for pancreatic cancer: the 'SPARC' trial protocol.
by: Holyoake, D, et al.
Published: (2016)

Future vision for the quality assurance of oncology clinical trials
by: Thomas eFitzGerald, MD, et al.
Published: (2013-03-01)

ARCII: A Phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer
by: Wilson, J, et al.
Published: (2016)

Metal artefact reduction for accurate tumour delineation in radiotherapy
by: Kovacs, D, et al.
Published: (2017)

Quality assurance of four-dimensional computed tomography in a multicentre trial of stereotactic body radiotherapy of centrally located lung tumours
by: Marie Lambrecht, et al.
Published: (2018-10-01)

Gross Tumor Delineation in Esophageal Cancer on MRI Compared With 18F-FDG-PET/CT
by: Sophie E. Vollenbrock, MD, et al.
Published: (2019-10-01)

The diagnostic accuracy of intraoperative differentiation and delineation techniques in brain tumours
by: Laura Van Hese, et al.
Published: (2022-11-01)

Prognostic value of gross tumor volume delineated by FDG-PET-CT based radiotherapy treatment planning in patients with locally advanced pancreatic cancer treated with chemoradiotherapy
by: Parlak Cem, et al.
Published: (2012-03-01)

MRI to delineate the gross tumor volume of nasopharyngeal cancers: which sequences and planes should be used?
by: Popovtzer Aron, et al.
Published: (2014-09-01)

SCOPE1: a randomised phase II/III multicentre clinical trial of definitive chemoradiation, with or without cetuximab, in carcinoma of the oesophagus
by: Staffurth John N, et al.
Published: (2011-10-01)

Driving developments in UK oesophageal radiotherapy through the SCOPE trials
by: S. Gwynne, et al.
Published: (2019-02-01)

Delineation uncertainties of tumour volumes on MRI of head and neck cancer patients
by: Ruta Zukauskaite, et al.
Published: (2022-09-01)

Intermodality Variability in Gross Tumor Volume Delineation for Radiation Therapy Planning in Oropharyngeal Squamous Cell Carcinoma
by: Thaskeen S. Fathima, MD, et al.
Published: (2024-05-01)

Analysis of on-trial quality assurance for the SPARC clinical trial using novel peer-review methodology
by: Holyoake, D, et al.
Published: (2018)

Gross Domestic Product (GDP) and productivity of schizophrenia trials: an ecological study
by: Fenton Mark, et al.
Published: (2003-12-01)

Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial.
by: Crosby, T, et al.
Published: (2013)

Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/− cetuximab in oesophageal cancer
by: Crosby, T, et al.
Published: (2017)

Impact of metal artifact reduction algorithm on gross tumor volume delineation in tonsillar cancer: reducing the interobserver variation
by: Yoshiyuki Fukugawa, et al.
Published: (2022-09-01)

Evaluation of Hybrid PET/MRI for Gross Tumor Volume (GTV) Delineation in Colorectal Cancer Liver Metastases Radiotherapy
by: Zhang YN, et al.
Published: (2021-07-01)

Symmetry Adapted Assur Decompositions
by: Anthony Nixon, et al.
Published: (2014-06-01)

Ensuring trial validity by data quality assurance and diversification of monitoring methods.
by: Baigent, C, et al.
Published: (2008)